Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2003

View Archived Issues

Beneficial effects reported for duloxetine in primary fibromyalgia

LJP-394 well tolerated in SLE patients with renal disease

Milnacipran as a potential therapy for FMS

Immunomodulatory effects of OM-89 in rheumatoid arthritis patients

Studies on lumiracoxib in rheumatoid arthritis presented at ACR meeting

Immunomodulating activity reported for LymphoStat-B in monkeys and SLE patients

Sankyo describes the isolation of a 2'-PDE inhibitor with utility in viral infections

First North American trial of Adhibit

Levaquin approved for five-day treatment of CAP

Millennium and Bayer alliance concludes

New inhibitors of ZAP-70, FAK and/or Syk designed at Novartis

Indian group identifies new antiallergic/antiasthmatic agents

Servier team presents new 5-HT2C antagonists for anxiety and other disorders

Apotex researchers prepare and test new factor XIIIa inhibitors

Two series of PDE7 inhibitors and their use presented by Warner-Lambert (Pfizer) scientists

Novel HIV integrase inhibitors claimed by Merck

Novartis describes new CCR3 antagonists with utility in asthma therapy

Sankyo intensifies development of anticancer drugs

Sifrol approved for the treatment of Parkinson's disease

Raptiva approved for chronic, moderate to severe plaque psoriasis

Approvable letter received for Ariflo

Canadian approval for Gleevec for newly diagnosed Ph+ CML

European enrollment commences in phase II trial for DAC:GLP-1

Development of KW-6002 temporarily suspended

Prodrugs of CO/CO2 associated with clinical and radiographic improvement in arthritis

Targeted therapy of AML with anti-FLT3 antibody under evaluation

Anticytokine drug in development at Kowa for oral therapy of arthritis

Microbially produced inhibitor of bacteria-specific enzyme discovered

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...